



(51) International Patent Classification:

C07K 16/24 (2006.01) A61P 29/00 (2006.01)
A61K 39/395 (2006.01) A61P 37/00 (2006.01)
A61K 47/68 (2017.01) C12N 15/85 (2006.01)

(21) International Application Number:

PCT/US2025/014119

(22) International Filing Date:

31 January 2025 (31.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/627,553 31 January 2024 (31.01.2024) US

(71) Applicant: **D2M BIOTHERAPEUTICS LIMITED**; Ser-tus Chambers, Governors Square, Suite #5-204, 23 Lime Tree Bay Avenue, P.O. Box 2547, Grand Cayman, KY-1104 (KY).

(71) Applicant (for SC only): **D2M BIOTHERAPEUTICS INC.** [US/US]; 22 Strathmore Rd., Natick, Massachusetts 01760 (US).

(72) Inventors: **BING, Nan**; 22 Strathmore Rd., Natick, Massachusetts 01760 (US). **JIANG, Xiaodong**; 22 Strathmore Rd., Natick, Massachusetts 01760 (US). **ZHANG, Dong**; 22 Strathmore Rd., Natick, Massachusetts 01760 (US). **HU, Guangan**; 22 Strathmore Rd., Natick, Massachusetts 01760 (US). **ZHAO, Qianju**; 22 Strathmore Rd., Natick, Massachusetts 01760 (US). **SUN, Zhengwang**; 22 Strathmore Rd., Natick, Massachusetts 01760 (US). **HOU, Tianfei**; 22 Strathmore Rd., Natick, Massachusetts 01760 (US).

(74) Agent: **LIN, Peng** et al.; FISH & RICHARDSON P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: ANTI-IL12P35 ANTIBODIES AND USES THEREOF




FIG. 31B

(57) Abstract: This disclosure relates to anti-IL12p35 (interleukin 12 subunit alpha) antibodies, antigen-binding fragments, and the uses thereof. In some embodiments, the anti-IL12p35 antibodies or antigen-binding fragments thereof described herein can be used for treating systemic sclerosis (SSc), primary biliary cholangitis (PBC), systemic lupus erythematosus (SLE), and/or Sjogren's syndrome (SjS).

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*